Last reviewed · How we verify

NCT03493191

A Single Dose Study of SHR0410 in Healthy Male Participants

Completed Phase 1 Last updated 26 February 2019
What this trial tests

Phase 1 trial testing 0.5μg/kg SHR0410 in Acute Pain in 48 participants. Completed in 14 July 2018.

Timeline
15 April 2018
Primary endpoint
29 June 2018
14 July 2018

Quick facts

Lead sponsorAtridia Pty Ltd.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment48
Start date15 April 2018
Primary completion29 June 2018
Estimated completion14 July 2018
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Atridia Pty Ltd. — full company profile →

Who can join

Adults 18 to 45, male only, with Acute Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to investigate the effect of a single intravenous (IV) dose of SHR0410 at 6 dose levels (0.5 μg/kg, 1 μg/kg, 2 μg/kg, 5 μg/kg, 10 μg/kg and 20 μg/kg) in healthy participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Pain

Currently open trials in the same condition.

Other Atridia Pty Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03493191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing